Editorial
doi: 10.1111/j.1440-1746.2011.06901.x.
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
- PMID: 22011294
- DOI: 10.1111/j.1440-1746.2011.06901.x
Item in Clipboard
Editorial
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
J Gastroenterol Hepatol.
2011 Nov.
No abstract available
Comment on
-
Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.J Gastroenterol Hepatol. 2011 Nov;26(11):1612-8. doi: 10.1111/j.1440-1746.2011.06751.x. J Gastroenterol Hepatol. 2011. PMID: 21517968
Similar articles
-
Major achievements in hepatocellular carcinoma.Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0. Lancet. 2009. PMID: 19231618 No abstract available.
-
Sorafenib in hepatocellular carcinoma.Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669. Br J Hosp Med (Lond). 2010. PMID: 20852487 Review.
-
Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.Dig Liver Dis. 2012 May;44(5):361-2. doi: 10.1016/j.dld.2012.02.014. Epub 2012 Mar 14. Dig Liver Dis. 2012. PMID: 22424640 No abstract available.
-
[Hepatocellular carcinoma - long-term treatable disease].Klin Onkol. 2012;25(4):287-9. Klin Onkol. 2012. PMID: 22920170 Czech.
-
[Hepatocellular carcinoma].Nihon Rinsho. 2010 Oct;68(10):1861-5. Nihon Rinsho. 2010. PMID: 20954330 Review. Japanese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
